This article is more than 5 years old. Information may no longer be current.
Biomarkers differentiated lung cancer, nontumor lung pathologies
Click Here to Manage Email Alerts
Researchers at Saarland University in Germany have identified potential serum-based biomarkers that may detect lung cancer, and these biomarkers appear to differentiate between patients with lung cancer and patients with nontumor lung pathologies.
The researchers used 82 phage-peptide clones in the serological spot assay. One-third of the clones on the profile were previously identified in squamous cell lung cancer. The researchers also included clones isolated from a fetal brain library and clones that are immunogenic in brain cancer, which are potentially immunogenic in other cancers.
The researchers screened 108 sera: 39 from patients with squamous cell lung cancer, 29 sera from patients with other nontumor lung pathologies and 40 sera from healthy volunteers.
Using a Naïve Bayes Classifiers approach, the researchers were able to differentiate between squamous cell carcinoma and normal sera with 93.1% specificity, 92.9% sensitivity and 93% accuracy. They also differentiated between squamous cell carcinoma and nontumor lung pathologies with 93.5% specificity, 75.2% sensitivity and 83% accuracy.
Fourteen of the clones reacted to the squamous cell carcinoma sera. Three of those did not react to the normal sera or the nontumor lung pathology sera. The three clones had homology to ROCK1, PRKCB1 and KIAA0376.
Int J Cancer. 2008;123:1631-1636.